Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
Multicenter, multinational, randomized, 3-arm, double-blind, phase II clinical study with 2400mg mesalamine, 1200mg mesalamine or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients for 2 years.
创建时间：
2017-11-15
